| Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Appointment of Chief Financial Officer
On September 30, 2025, the Board of Directors (the “Board”) of Climb Bio, Inc. (the “Company”) appointed Susan Altschuller, Ph.D., MBA, as Chief Financial Officer and Treasurer of the Company and designated her as the Company’s principal financial officer, effective as of October 1, 2025 (the “Effective Date”).
Susan Altschuller, Ph.D., MBA, 44, most recently served as Chief Financial Officer of Dragonfly Therapeutics, Inc., a private biotechnology company, from August 2024 to December 2024. Prior to that, she served as the Chief Financial Officer of Cerevel Therapeutics, Inc. (“Cerevel”), a publicly traded clinical-stage biopharmaceutical company, from May 2023 until its acquisition by AbbVie Inc. in August 2024. Prior to joining Cerevel, Dr. Altschuller was Chief Financial Officer of ImmunoGen, Inc. (“ImmunoGen”), a publicly traded biopharmaceutical company, from July 2020 to March 2023. Before ImmunoGen, Dr. Altschuller worked at Alexion Pharmaceuticals, Inc., a global biopharmaceutical company, where she served as Head of Enterprise Finance from April 2020 to July 2020 and Head of Investor Relations from January 2018 to April 2020. From February 2017 to January 2018, Dr. Altschuller was Head of Investor Relations at Bioverativ Inc., a multinational biotechnology company created from a separation of Biogen Inc.’s (“Biogen”) global hemophilia business. Early in her career, Dr. Altschuller held positions at Biogen in various functions of increasing responsibility, including investor relations, corporate finance, and commercial finance. Dr. Altschuller holds a BSE in Biomedical Engineering with honors from Tulane University, a Ph.D. in biomedical engineering from the Illinois Institute of Technology, and an MBA from the MIT Sloan School of Management. She previously served as a director of Mural Oncology plc from November 2023 to September 2024, and is a founding board member of the HNRNP Family Foundation.
Pursuant to an offer letter (the “Offer Letter”), dated September 30, 2025, between the Company and Dr. Altschuller governing the terms of her employment, Dr. Altschuller will be paid a base salary of $510,000 per year. Dr. Altschuller will also be eligible to receive an annual discretionary bonus of up to 40% of her annualized base salary each year, as determined by the Board in its sole discretion. Also, as a condition to her employment and pursuant to the Offer Letter, Dr. Altschuller will enter into a confidential information, inventions assignment, non-competition and non-solicitation agreement with the Company.
Effective as of the Effective Date, the Board granted to Dr. Altschuller a stock option to purchase 600,000 shares of the Company’s common stock (the “Common Stock”) at an exercise price per share equal to the closing price of the Common Stock on The Nasdaq Global Market on the Effective Date (the “Option”). The Option was granted pursuant to the Company’s 2025 Inducement Plan, as amended, and will vest as to 25% of the shares underlying the Option on the first anniversary of the Effective Date and in 36 equal monthly installments thereafter, subject to Dr. Altschuller’s continued service.
In addition, the Offer Letter provides that Dr. Altschuller will be eligible to participate in benefits plans offered to similarly-situated employees by the Company, subject to plan terms and generally applicable Company policies. In the event that the Company terminates Dr. Altschuller’s employment without cause (as defined in the Offer Letter) or Dr. Altschuller resigns for good reason (as defined in the Offer Letter) at any time that is not during the three months prior to, as of, or within twelve months following the effective date of a change in control (as defined in the Offer Letter) and subject to the satisfaction of certain conditions, including Dr. Altschuller’s execution of a separation agreement containing an effective, general release of claims in favor of the Company, the Company will be obligated to (1) (a) in the case where Dr. Altschuller has been employed with the Company for at least 12 months, pay to Dr. Altschuller in a single lump sum an amount equal to nine months of her then current base salary and the amount of her target annual discretionary bonus opportunity for the year in which the termination of her employment occurs (the “Target Amount”), or (b) in the case where Dr. Altschuller has been employed with the Company for less than 12 months, pay to Dr. Altschuller in a single lump sum an amount equal to four months of her then current base salary and the Target Amount, (2) make payments for the continuation of Dr. Altschuller’s health coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) for a period of (a) in the case where Dr. Altschuller has been employed with the Company for at least 12 months, up to
